BrainStorm Cell Therapeutics Proposes FDA Regulatory Reforms for ALS and Regenerative Medicine Clinical Trials

BrainStorm Cell Therapeutics published a paper this week advocating for the U.S. Food and Drug Administration (FDA) to modernize its regulatory framework regarding amyotrophic lateral sclerosis (ALS), rare diseases, and regenerative medicine. The publication outlines specific recommendations for how federal regulators might adjust clinical trial designs and approval pathways to better accommodate the unique challenges associated with developing therapies for neurodegenerative conditions.

The paper suggests that the current regulatory landscape requires greater flexibility to address the rapid progression of diseases like ALS. It proposes that the FDA incorporate more patient-centric endpoints and utilize adaptive trial designs that allow for real-time data adjustments. Furthermore, the authors argue that the agency should increase its reliance on surrogate biomarkers to accelerate the evaluation of regenerative medicine products. By proposing these structural changes, the publication aims to facilitate a more efficient review process for innovative treatments that currently face significant hurdles under existing clinical trial standards.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI